Immunotherapy of autoimmunity and cancer: the penalty for success

Advances in our understanding of autoimmunity and tumour immunity have led to improvements in immunotherapy for these diseases. Ironically, effective tumour immunity requires the induction of the same responses that underlie autoimmunity, whereas autoimmunity is driven by dysregulation of the same mechanisms that are involved in host defence and immune surveillance. Therefore, as we manipulate the immune system to treat cancer or autoimmunity, we inevitably unbalance the vital mechanisms that regulate self tolerance and antimicrobial resistance. This Science and Society article aims to dissect the conundrum that is inherent to the concept of immunotherapy and highlights the need for new and more specific therapeutic approaches.

[1]  S. Miller,et al.  Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease , 2007, Nature Reviews Immunology.

[2]  E. Small,et al.  A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer , 2007, Clinical Cancer Research.

[3]  C. Robert,et al.  What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? , 2009, The oncologist.

[4]  Nitin J. Karandikar,et al.  The mechanism of action of glatiramer acetate treatment in multiple sclerosis , 2010, Neurology.

[5]  M. Raffeld,et al.  Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes , 2002, Science.

[6]  Nicki Panoskaltsis,et al.  Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. , 2006, The New England journal of medicine.

[7]  A. Marmont Will hematopoietic stem cell transplantation cure human autoimmune diseases? , 2008, Journal of autoimmunity.

[8]  D. Arnold,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.

[9]  M. Feldmann,et al.  Development of anti-TNF therapy for rheumatoid arthritis , 2002, Nature Reviews Immunology.

[10]  M. Freedman,et al.  Efficacy of Disease-Modifying Therapies in Relapsing Remitting Multiple Sclerosis: A Systematic Comparison , 2008, European Neurology.

[11]  R. Good Relations between immunity and malignancy. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[12]  D. Gjertson,et al.  TNFα blockade in human diseases : An overview of efficacy and safety , 2008 .

[13]  S. Rosenberg,et al.  Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study , 2005, Annals of Surgical Oncology.

[14]  O. Finn,et al.  Cancer vaccines: a promising cancer therapy against all odds. , 2007, Future oncology.

[15]  A. Evans,et al.  Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial , 2000, Nature Medicine.

[16]  M. Mochizuki,et al.  Cellular autoimmunity to retinal specific antigens in patients with Behçet's disease. , 1993, The British journal of ophthalmology.

[17]  A. Feldman,et al.  Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  T. Waldmann Anti-Tac (daclizumab, Zenapax) in the Treatment of Leukemia, Autoimmune Diseases, and in the Prevention of Allograft Rejection: A 25-Year Personal Odyssey , 2007, Journal of Clinical Immunology.

[19]  G. Adams,et al.  Monoclonal antibody therapy of cancer , 1999, Nature Biotechnology.

[20]  M. Amagai Autoimmunity against desmosomal cadherins in pemphigus. , 1999, Journal of dermatological science.

[21]  F. Vincenti Costimulation blockade in autoimmunity and transplantation. , 2008, The Journal of allergy and clinical immunology.

[22]  H. Niitani,et al.  [Phase II study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[23]  S. Rosenberg,et al.  Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. , 2004, Journal of immunotherapy.

[24]  L. Adorini Cytokine‐based immunointervention in the treatment of autoimmune diseases , 2003, Clinical and experimental immunology.

[25]  S. Verma,et al.  Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer , 2008, Current oncology.

[26]  J. Frank,et al.  Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand , 2000, Nature Medicine.

[27]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Mochizuki,et al.  Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. , 2006, Investigative ophthalmology & visual science.

[29]  J. Lindstrom Acetylcholine receptors and myasthenia , 2000, Muscle & nerve.

[30]  T. Nomura,et al.  Regulatory T Cells and Immune Tolerance , 2008, Cell.

[31]  J. Browning B cells move to centre stage: novel opportunities for autoimmune disease treatment , 2006, Nature Reviews Drug Discovery.

[32]  D. Harlan,et al.  A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes , 2005, Diabetes.

[33]  J. Bluestone,et al.  CD3-specific antibodies: a portal to the treatment of autoimmunity , 2007, Nature Reviews Immunology.

[34]  Carmen Birchmeier,et al.  Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[35]  C. Rooney,et al.  Improving T cell therapy for cancer. , 2007, Expert opinion on biological therapy.

[36]  M. Debandt Lessons for lupus from tumour necrosis factor blockade , 2006 .

[37]  S. Rosenberg,et al.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy , 2008, Nature Reviews Cancer.

[38]  J. Passweg,et al.  Autologous stem cell transplantation in autoimmune diseases. , 2007, Seminars in hematology.

[39]  K. Norose,et al.  Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease. , 1996, The British journal of ophthalmology.

[40]  J. Rose,et al.  Monoclonal antibody treatments for multiple sclerosis , 2008, Current neurology and neuroscience reports.

[41]  L. Chatenoud Immune therapies of autoimmune diseases: are we approaching a real cure? , 2006, Current opinion in immunology.

[42]  D. Paty,et al.  TNF neutralization in MS , 1999, Neurology.

[43]  E. Zerhouni,et al.  The Biomarkers Consortium: public and private sectors working in partnership to improve the public health. , 2007, The Oncologist.

[44]  George Kollias,et al.  Uncoupling the Proinflammatory from the Immunosuppressive Properties of Tumor Necrosis Factor (Tnf) at the P55 TNF Receptor Level , 2001, The Journal of experimental medicine.

[45]  E. Arbustini,et al.  Immunosuppression and cancer: A comparison of risks in recipients of organ transplants and in HIV-positive individuals. , 2006, Transplantation proceedings.

[46]  V. Singh,et al.  Human S-antigen: peptide determinant recognition in uveitis patients. , 2004, Experimental and molecular pathology.

[47]  T. Waldmann,et al.  Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[48]  S. Rosenberg,et al.  Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  P. Lipsky,et al.  Infliximab in active early rheumatoid arthritis , 2004, Annals of the rheumatic diseases.

[50]  C. Scott The problem with potency , 2005, Nature Biotechnology.

[51]  L. Steinman,et al.  Design of effective immunotherapy for human autoimmunity , 2005, Nature.

[52]  D. Neuberg,et al.  Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients , 2008, Proceedings of the National Academy of Sciences.

[53]  B. Roep T-Cell Responses to Autoantigens in IDDM: The Search for the Holy Grail , 1996, Diabetes.

[54]  J. Schlom,et al.  Preclinical and clinical studies of recombinant poxvirus vaccines for carcinoma therapy. , 2007, Critical reviews in immunology.

[55]  Constant Beckers The search for the Holy Grail , 2007 .

[56]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[57]  M. Wei,et al.  Bacterial targeted tumour therapy-dawn of a new era. , 2008, Cancer letters.

[58]  Y. Suzuki,et al.  T cell immune responses against melanoma and melanocytes in cancer and autoimmunity. , 2000, Pigment cell research.

[59]  G. Parmiani,et al.  Cytokines in cancer therapy. , 2000, Immunology letters.